Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials have shown better survival and tumour response with gemcitabine and capecitabine than with gemcitabine alone in advanced or metastatic pancreatic cancer. We aimed to determine the efficacy and safety of gemcitabine and capecitabine compared with gemcitabine monotherapy for resected pancreatic cancer.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet

Title: Lancet (London, England)

Publisher: Elsevier BV

ISSN (Electronic): 1474-547X

ISSN (Print): 0140-6736

Publication date (Electronic): Mar 11 2017

Volume: 389

Issue: 10073

Affiliations

[1 ] University of Liverpool, Liverpool, UK; The Royal Liverpool University Hospital, Liverpool, UK. Electronic address: j.p.neoptolemos@liverpool.ac.uk.

[2 ] University of Liverpool, Liverpool, UK; The Clatterbridge Cancer Centre, Wirral, UK.

[3 ] The Royal Liverpool University Hospital, Liverpool, UK.

[4 ] University of Liverpool, Liverpool, UK.

[5 ] University of Manchester/The Christie NHS Foundation Trust, Manchester, UK.

[6 ] University of Liverpool, Liverpool, UK; The Royal Liverpool University Hospital, Liverpool, UK.

[7 ] The Clatterbridge Cancer Centre, Wirral, UK.

[8 ] Manchester Royal Infirmary, Manchester, UK.

[9 ] Royal Marsden Hospital, London, UK.

[10 ] Weston Park Hospital, Sheffield, UK.

[11 ] Royal Free Hospital, London, UK.

[12 ] St James's University Hospital, Leeds, UK.

[13 ] Karolinska Institute, Stockholm, Sweden; Clinical Research Sörmland, Eskilstuna, Sweden.

[14 ] University of Uppsala, Uppsala, Sweden.

[15 ] Bristol Haematology and Oncology Centre, Bristol, UK.

[16 ] University of Hamburg Medical institutions UKE, Hamburg, Germany.

[17 ] Royal Surrey County Hospital, Guildford, UK.

[18 ] Guy's Hospital, London, UK.

[19 ] Hammersmith Hospital, London, UK.

[20 ] The Beatson West of Scotland Cancer Centre, Glasgow, UK.

[21 ] Velindre Hospital, Cardiff, UK.

[22 ] Queen Elizabeth Hospital, Birmingham, UK.

[23 ] Churchill Hospital, Oxford, UK.

[24 ] Derriford Hospital, Plymouth, UK.

[25 ] Ipswich Hospital, Ipswich, UK.

[26 ] Skåne University Hospital, Lund, Sweden.

[27 ] University Hospital Coventry, Coventry, UK.

[28 ] Hôpital Beaujon, Clichy, France.

[29 ] University of Heidelberg, Germany.

Article

Publisher Item ID: S0140-6736(16)32409-6

DOI: 10.1016/S0140-6736(16)32409-6

PubMed ID: 28129987

SO-VID: ce220a9d-7b36-44fb-814f-31f0e6c4d059

History

Data availability:

Comments

Comment on this article

scite_

Cited by 607

See all cited by

- Version 1